[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-thromboembolic-pulmonary-hypertension-cteph\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-thromboembolic-pulmonary-hypertension-cteph":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,48,62,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100652652","exercise-performance-on-ambient-air-vs-low-flow-liquid-oxygen-therapy-in-chronic-lung-diseases-100652652",false,"NCT07777367","Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Chronic Lung Diseases","Exercise Performance on Ambient Air vs. Commonly Prescribed Nasal Low Flow Oxygen Therapy in Patients With Exercise Induced Desaturation Due to Pulmonary Disease","Inclusion Criteria:\n\n* Minimum 18 years of age\n* Written informed consent\n* Patients with diagnosed pulmonary arterial hypertension (PAH), distal chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD) with emphysema, COPD without emphysema, or interstitial lung disease\n* Former desaturation under exercise defined as SpO2-decrease \\>3%\n* Treated with a stable drug therapy (with no changes for at least 14 days prior to screening)\n\nExclusion Criteria:\n\n* Severe hypoxemia needing supplemental oxygen therapy defined as PaO2 \\\u003C 6.9 kPa\n* Inability or contraindications to undergo the investigated intervention\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, walk disability etc.","ALL","18 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","The investigators aim to study the effect of liquid oxygen therapy (4l\u002Fmin, nasal) )in Swiss residents with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension (PAH) or chronic thromboembolic pulmonary hypertension (CTEPH).",[26,27,28],"Pulmonary Vascular Disease","Chronic Thromboembolic Pulmonary Hypertension (CTEPH)","Pulmonary Arterial Hypertension (PAH)",[30,31,32,33,34],"Pulmonary Hypertension","Supplemental Oxygen Therapy","Pulmonary Arterial Hypertension","Chronic Thromboembolic Pulmonary Hypertension","6-Minute Walk Distance","RECRUITING","2026-08-17",{"date":38,"type":39},"2026-08-20","ACTUAL",{"date":41,"type":20},"2026-08-01",{"date":43,"type":20},"2028-12-31",{"name":45,"class":46},"Silvia Ulrich Somaini","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":14,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":24,"conditions":56,"keywords":57,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":58,"startDateStruct":59,"completionDateStruct":60,"leadSponsor":61,"locationsCount":47},"100652626","exercise-performance-on-ambient-air-vs-low-flow-liquid-oxygen-therapy-in-pulmonary-vascular-disease-pvd-100652626","NCT07777445","Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Pulmonary Vascular Disease (PVD)","Inclusion Criteria:\n\n* \\- Minimum 18 years of age\n* Written informed consent\n* Patients with diagnosed pulmonary arterial hypertension (PAH), distal chronic thromboembolic pulmonary hypertension (CTEPH), chronic obstructive pulmonary disease (COPD) with emphysema, COPD without emphysema, or interstitial lung disease\n* Former desaturation under exercise defined as SpO2-decrease \\>3%\n* Treated with a stable drug therapy (with no changes for at least 14 days prior to screening)\n\nExclusion Criteria:\n\n* \\- Severe hypoxemia needing supplemental oxygen therapy defined as PaO2 \\\u003C 6.9 kPa\n* Inability or contraindications to undergo the investigated intervention\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, walk disability etc.",{"count":19,"type":20},[23],[26,27,28],[30,31,32,33,34],{"date":38,"type":39},{"date":41,"type":20},{"date":43,"type":20},{"name":45,"class":46},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":66,"acronym":67,"eligibilityCriteria":68,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":69,"targetDuration":71,"studyType":72,"phases":4,"briefSummary":73,"conditions":74,"keywords":75,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100606190","what-is-the-role-of-the-exposome-in-pulmonary-hypertension-100606190","NCT07172334","What is the Role of the Exposome in Pulmonary Hypertension","EXPOSPAH","Inclusion Criteria:\n\n* Consent signed by the participant\n* Age ≥ 18 years\n* Free subject, under no legal protection\n* Good understanding of the French language, allowing to answer the questionnaires\n* Patients with pre-capillary PH confirmed by cardiac catheterization (PAPm \\> 20mmHg, PCP ≤ 15 mmHg, RVP \\> 2UW) having had the right diagnostic cardiac catheterization within one year (≤1 year) :\n\n  * Cases: Patients with PAH without associated pathology: idiopathic or heritable, or with features of venous\u002Fcapillary involvement, according to the clinical classification of PH\n  * Controls: Patients with chronic thromboembolic PH (CTEPH, class 4), according to the clinical classification of PH.\n\nExclusion Criteria:\n\n* Patients classified as HTP groups 2, 3 or 5\n* Patients with a diagnosis of PAH associated with a connective tissue disease, HIV, portal hypertension, congenital heart disease, bilharzia, or a drug or toxic cause considered certain according to the international classification (Aminorex, Benfluorex, Carfilzomib, Dasatinib, Dexfenfluramine, Fenfluramine, Methamphetamines, Mitomycin C, adulterated rapeseed oil)\n* Patients with signs of right heart failure requiring amines and\u002For intensive care hospitalization at time of visit (may be included at a later visit)\n* Patients refusing hair sampling or having no hair \\> 2 cm to allow sampling\n* Patients benefiting from enhanced protection, i.e. minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social establishment, adults under legal protection, and patients in emergency situations",{"count":70,"type":20},150,"1 Day","OBSERVATIONAL","Pulmonary arterial hypertension (PAH) is a rare and incurable disease affecting people of all ages. It is characterized by obstructive remodeling of the small pulmonary arteries, responsible for an increase in pulmonary arterial pressure, leading to right heart failure and death in the absence of treatment. PAH can be associated with a variety of diseases, but around half of all PAH cases are idiopathic or hereditary, and may develop on predisposed terrain following a \"second hit\", as suggested by the identification of PAH cases associated with the use of anorectic drugs, methamphetamine and occupational exposure to organic solvents. No study has systematically analyzed the exposome of patients with PAH, combining environmental and occupational exposures as well as drugs and medications.\n\nThe exposome of patients with PAH without associated causes will be compared with that of patients with another form of pulmonary hypertension (PH), linked to thromboembolic risk factors: chronic thromboembolic PH (CTEPH), which will constitute the control group.",[28,27],[76,77],"Pulmonary hypertension","Exposome","NOT_YET_RECRUITING","2026-07-20",{"date":81,"type":39},"2026-07-22",{"date":83,"type":20},"2027-01",{"date":85,"type":20},"2029-01",{"name":87,"class":46},"Poitiers University Hospital",10,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":123},"100643856","vasopressor-agents-in-pulmonary-hypertension-crisis-100643856","NCT07667829","Vasopressor Agents in Pulmonary Hypertension Crisis","Comparison of the Efficacy and Safety of Dopamine, Norepinephrine and Epinephrine in the Treatment of Pulmonary Hypertensive Crisis Under Hemodynamic Monitoring","Inclusion Criteria:\n\n1. Age \\> 18 years old;\n2. Signed informed consent form;\n3. Confirmed diagnosis of arterial pulmonary hypertension (PAH) and\u002For chronic thromboembolic pulmonary hypertension (CTEPH);\n4. Presenting with manifestations of pulmonary hypertensive crisis;\n5. Receiving both diagnosis and treatment in-hospital;\n6. No intravenous administration of the vasopressor drugs (including dopamine, norepinephrine, and epinephrine) under study at enrollment.\n\nExclusion Criteria:\n\n1. At SCAI stage D or stage E ;\n2. Patients who only receive a diagnosis but no treatment in the hospital;\n3. Uncontrolled hyperthyroidism;\n4. Complicated with angle-closure glaucoma;\n5. Hypersensitivity to the study drug;\n6. Ongoing use of halogenated hydrocarbon general anesthetics such as cyclopropane and halothane;\n7. Ongoing use of monoamine oxidase inhibitor (MAOI) antidepressants or anti-Parkinson drugs (phenelzine, tranylcypromine, isocarboxazid, moclobemide);\n8. Pregnancy;\n9. Already receiving the vasopressor drugs (dopamine, norepinephrine, epinephrine) under study at enrollment.",{"count":97,"type":20},75,[23],"Comparison of the efficacy and safety of three vasoactive agents-dopamine, norepinephrine, and epinephrine-in the treatment of patients with pulmonary hypertension crisis: prospective, randomised controlled trial monitored by haemodynamic monitoring",[28,27,101],"Hypertension, Pulmonary",[101,103,104,105,106,107,108,109,110,111,112,32],"Cardiovascular Diseases","Vascular Diseases","Dopamine","Norepinephrine","Epinephrine","Haemodynamic Monitoring","Efficacy and Safety","Chronic thromboembolic pulmonary hypertension","Heart Failure","Pulmonary circulation","2026-06-21",{"date":115,"type":39},"2026-06-25",{"date":117,"type":20},"2026-06",{"date":119,"type":20},"2029-01-31",{"name":121,"class":122},"China National Center for Cardiovascular Diseases","OTHER_GOV",3]